Drugs / rose bengal disodium
rose bengal disodium
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02693067 | Jul 2016 → Sep 2021 | neuroendocrine neoplasm | Provectus Biopharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT00986661 | Oct 2009 → Dec 2022 | breast cancer, colorectal cancer, hepatocellular carcinoma, lung cancer +4 | Provectus Biopharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02322086 | Jan → Dec 2015 | psoriasis | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01247818 | Dec 2010 → Aug 2011 | psoriasis | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00941278 | Jul → Dec 2009 | psoriasis | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00690807 | Jun 2008 → Aug 2009 | atopic eczema | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT06271772 | Jul 2024 → Jun 2026 overdue | keratitis | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05110001 | Aug 2022 → Dec 2024 | Acanthamoeba keratitis, fungal keratitis | University of California, San Francisco | Completed | Missed primary |
| Phase 3 | NCT04837664 | Jul 2018 → Dec 2020 | candidiasis | King Saud University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rose bengal disodium | “PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin” NCT01247818 ↗4“PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin” NCT00941278 ↗ “PH-10 is a formulation of rose bengal disodium (RB) for topical administration to the skin.” NCT00690807 ↗ |
| Known as | PH-10 | “PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin” NCT01247818 ↗ |
| Known as | PV-10 | “PV-10 (10% rose bengal disodium)” NCT00986661 ↗ |
| Known as | Rose Bengal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05110001 ↗ |
| Known as | Rose Bengal Sodium | “A phase 1 study to assess the safety, tolerability and effectiveness of PV-10 (Rose Bengal Sodium) in neuroendocrine tumours metastatic to the liver.” PMID 40140696 ↗ Mar 2025 |
| Route | Topical | “PH-10 is a formulation of rose bengal disodium (RB) for topical administration to the skin.” NCT00690807 ↗ |